Thus, the clinical genetics observations of CRC, and experimental observations from both in vivo mouse studies and ex vivo models, suggest that initiation of the serrated route has high reliance on epigenetic inactivation of regulators of the Wnt and senescence pathways, which allows oncogenic BRAF mutations to effectively drive tumorigenesis. The gene discussed is BRAF; the disease is colorectal carcinoma.